C5AR1 and neurodegenerative disease: In addition, PMX205 presented a higher brain penetration capacity than PMX53, which has enabled its use in several models of neurodegenerative diseases (40–42) Currently, these peptide antagonists are the most widely used inhibitors for the study of C5aR1/CD88 (20).